Michael Crutchlow

Michael Crutchlow currently serves as the Vice President and Head of Translational Medicine at Kallyope since June 2022. Prior to this role, Michael held several key positions at Merck from June 2007 to June 2022, including Executive Director of Late Stage Clinical Research for Diabetes and Endocrinology, where responsibilities included chairing product development teams and overseeing Phase 2-3 programs in NASH and Diabetes-Endocrinology. Michael also served as Executive Director of Clinical Pharmacology and Experimental Therapeutics, focusing on early-phase clinical strategy, and as Diabetes-Endocrinology Lead in Merck Experimental Medicine, where Michael developed translational and biomarker strategies for early-stage clinical programs. Other roles at Merck included Director of Early Clinical Biologics Development and Associate Director of Clinical Pharmacology, both of which involved strategy development for various therapeutic programs.